Treats obsessive compulsive disorder (OCD). ANDA 91482, held by Actavis Elizabeth. Fluvoxamine Maleate.
As of Nov 21, 2026, ANDA 91482 (Fluvoxamine Maleate), held by Actavis Elizabeth, was first approved by FDA on Nov 18, 2013, with 5 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults. Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1, 14.3 ). One maintenance study with IR fluvoxamine tablets. 1.1 Obsessive Compulsive Disorder
| Nov 18, 2013 | Original application | Approved | None posted |
| Apr 23, 2013 | Original application | Approved | None posted |
| Fluvoxamine Maleate100MG ยท capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate150MG ยท capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Feb 12, 2024 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Aug 18, 2023 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Aug 10, 2023 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Nov 18, 2013 | Original application | Approved | None posted |
| Apr 23, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters